May 15th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Novo Nordisk A/S reports that in the Frontier 2 study, their once-weekly and once-monthly Mim8 treatments significantly outperformed standard and prior prophylaxis treatments in reducing bleeding episodes in individuals with haemophilia A.

Mabwell reported progress in its clinical trial of the novel Nectin-4 targeting ADC (9MW2821) for triple-negative breast cancer treatment.

AC Immune and Takeda Enter an Exclusive Deal for Licence and Option on Active Immunotherapy Focused on Amyloid Beta for Alzheimer's Disease.

Kodiak Sciences has started treating initial participants in the Phase 3 GLOW2 study, examining Tarcocimab Tedromer for diabetic retinopathy.

Ajax Therapeutics has received FDA approval for its investigational new drug application for AJ1-11095, a novel Type II JAK2 inhibitor, intended for the management of myelofibrosis.

FDA grants priority review to Dupixent® (dupilumab) sBLA for treating teens with chronic rhinosinusitis and nasal polyps.

Cardurion Pharmaceuticals Reports Encouraging Outcomes from Phase 2a CARDINAL-HF Study of PDE9 Inhibitor in Heart Failure Patients.

Anaptys released encouraging initial outcomes from the GEMINI-2 Phase 3 study of Imsidolimab (IL-36R) for treating Generalized Pustular Psoriasis.

First Wave will concentrate on advancing a portfolio of gastrointestinal disease therapies, including latiglutenase, which encompasses multiples late-stage clinical assets.

Fusion Pharmaceuticals revealed that the initial participant has received a dose in the AlphaBreak Trial's Phase 2 study of FPI-2265 for treating metastatic castration-resistant prostate cancer.

Celltrion USA now offers a budget-friendly adalimumab-aaty biosimilar as an alternative to HUMIRA® at reduced wholesale prices.